Bausch + Lomb Reports Q1 2025 Financial Results

Bausch + Lomb Corporation ( (BLCO) ) has released its Q1 earnings. Here is a breakdown of the information Bausch + Lomb Corporation presented to its investors.

Bausch + Lomb Corporation is a global leader in eye health, offering a wide range of products including contact lenses, pharmaceuticals, and surgical devices, with a strong presence in over 100 countries. The company recently released its first-quarter 2025 financial results, highlighting a revenue increase and strategic advancements despite facing some financial challenges.

In the first quarter of 2025, Bausch + Lomb reported a revenue of $1.137 billion, marking a 3% increase from the previous year, with growth driven by its Vision Care and Surgical segments. However, the company faced a GAAP net loss of $212 million, attributed to increased selling costs and a voluntary recall of enVista intraocular lenses.

The Vision Care segment saw a 5% revenue growth on a constant currency basis, driven by strong sales of Daily SiHy lenses and over-the-counter products like LUMIFY. The Surgical segment also experienced an 11% growth, fueled by demand for implantables and equipment. Despite these gains, the Pharmaceuticals segment remained flat, with a slight decline in the U.S. Generics business.

Looking ahead, Bausch + Lomb has updated its full-year 2025 guidance to account for the enVista recall and foreign exchange impacts. The company remains focused on long-term growth and enhancing eye health standards, with plans for new clinical studies and product advancements.